• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira Pharm Inc (NQ: PCRX )

    15.50 +0.32 (+2.11%)
    Streaming Delayed Price Updated: 11:20 AM EDT, Sep 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Pacira Pharm Inc

    < Previous 1 2 3 4 Next >
    Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
    On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75. 
    Via Investor's Business Daily
    Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
    Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
    Via Investor's Business Daily
    Vertex Pharmaceuticals Receives Composite Rating Upgrade
    The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals. 
    Via Investor's Business Daily
    Pacira BioSciences's Return on Invested Capital Overview
    Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. 
    Via Benzinga
    Gilead Stock Earns Rating Upgrade After Quick Turnaround
    A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
    Via Investor's Business Daily
    Pacira BioSciences: Q1 Earnings Insights
    Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Expert Ratings For Pacira BioSciences
    Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the... 
    Via Benzinga
    Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know
    Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
    Via Benzinga
    Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
    On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
    Via Investor's Business Daily
    28 Biggest Movers From Yesterday
    Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
    Via Benzinga
    Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
    On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
    Via Investor's Business Daily
    Stocks That Hit 52-Week Highs On Thursday
    On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
    Via Benzinga
    Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
    On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
    Via Investor's Business Daily
    Apellis Pharmaceuticals Stock Shows Rising Relative Strength
    Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
    Via Investor's Business Daily
    Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
    Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
    Via Investor's Business Daily
    Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
    Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
    Via Investor's Business Daily
    Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
    Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
    Via Investor's Business Daily
    The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
    Via Benzinga
    The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
    Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
    Via Benzinga
    Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
    The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
    Via Investor's Business Daily
    Bear Market Bets In Biotech
    Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
    Via Talk Markets
    Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript
    PCRX earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
    Via Benzinga
    Topics Retirement
    Exposures Pension
    Earnings Scheduled For November 3, 2021
    Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
    Via Benzinga
    The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
    Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
    Via Benzinga
    The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
    Via Benzinga
    Exposures COVID-19
    Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
    Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition
    Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value... 
    Via Benzinga
    Why Pacira Biosciences Stock Sank Today
    A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug. 
    Via The Motley Fool
    Exposures Product Safety
    The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.